In recent years, RBP4 has been shown to contribute to the development of insulin resistance and a range of metabolic disorders such as type 2 diabetes mellitus, gestational diabetes, obesity, metabolic syndrome, hyperuricaemia, metabolic dysfunction-associated steatotic liver disease (MASLD), and cardiorenal diseases. Here, RBP4 is linked to metabolic dysfunction-associated steatotic liver disease.